LIVE
Epitalon, Khavinson short-peptide bioregulators, FOXO4-DRI, and longevity cofactors (NAD+, glutathione) studied for aging and tissue-specific regeneration.
The bulk of this category derives from decades of work by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. Each Khavinson peptide is a di-, tri-, or tetra-peptide proposed to selectively modulate gene expression in a target tissue: Vilon (Lys-Glu, immune), Epitalon (Ala-Glu-Asp-Gly, pineal and telomere), Cartalax (cartilage), Pinealon (pineal / CNS), Livagen (liver), Pancragen (pancreas), and additional entries targeting heart (Cardiogen), lung (Chonluten), prostate (Prostamax), testis (Testagen), and bronchial (Bronchogen) tissue.
Clinical evidence for the Khavinson bioregulators sits primarily in Russian-language gerontology cohorts with limited independent Western replication. Vendors typically sell them under the Latin trade names and a range of generic codes.
Non-Khavinson longevity peptides cover different mechanisms. FOXO4-DRI is a D-retro-inverso peptide designed by the de Keizer lab at Erasmus MC to disrupt the FOXO4–p53 interaction in senescent cells, studied as a senolytic research tool. Humanin is a 24-amino-acid mitochondrial-derived peptide with cytoprotective effects in models of neurodegeneration and metabolic stress. NAD+ and glutathione are catalogued alongside the peptide class despite being small molecules, because they share the longevity-supplement commercial context.
None of the members in this category hold FDA approval for an anti-aging indication. All are sold as research-use-only lyophilized compounds.